WO2007112964A1 - Novel use of ascorbigen - Google Patents

Novel use of ascorbigen Download PDF

Info

Publication number
WO2007112964A1
WO2007112964A1 PCT/EP2007/002858 EP2007002858W WO2007112964A1 WO 2007112964 A1 WO2007112964 A1 WO 2007112964A1 EP 2007002858 W EP2007002858 W EP 2007002858W WO 2007112964 A1 WO2007112964 A1 WO 2007112964A1
Authority
WO
WIPO (PCT)
Prior art keywords
ascorbigen
use according
condition
composition
mammal
Prior art date
Application number
PCT/EP2007/002858
Other languages
French (fr)
Inventor
Luca Barella
Bernd Mussler
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2007112964A1 publication Critical patent/WO2007112964A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a novel use of ascorbigen; in particular it relates to the use of ascorbigen to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.
  • Ascorbigen is a known indol derivative which can be isolated from cabbage juice or synthetically prepared from ascorbic acid and 3-hydroxymethylindole.
  • ascorbigen is a mixture of 2-C(1 H-indol-3-ylmethyl)- ⁇ -L-lyxo-3- hexulofuranosonic acid ⁇ -lactone and 2-C(1 H-indol-3-ylmethyl)- ⁇ -L-xylo-3- hexulofuranosonic acid ⁇ -lactone.
  • the term "ascorbigen” comprises the particular enantiomeres each individually as well as the above mentioned mixture and (stereo-) isomers and mixtures thereof.
  • ARE antioxidant response element
  • Nrf2 which is normally sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (Kepti ), dissociates from it upon exposure to ARE-mediated inducers, translocates to the nucleus, complexes with other nuclear factors, and binds to ARE.
  • ARE-regulated gene products include Phase Il enzymes such as glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1 , UDP- glucuronosyltransferase, gamma-glutamate cysteine ligase, and hemeoxygenase-1.
  • ARE activators such as oltipraz, anethole dithiolethione, sulforaphane, 6-methylsulphinylhexyl isothiocyanate, curcumin, caffeic acid phenethyl ester, 4'-bromoflavone, etc. are considered to have a potential in (chemo-) preventing and/or hindering the development of cancer, degenerative agents, etc.
  • CONFIRMATION COPY processes and/or age related diseases in a mammal, including neurological decay, Alzheimer, increasing oxidative stress, muscle decay.
  • the present invention relates to the use of ascorbigen to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.
  • the invention relates to a method of inhibiting, preventing and/or hindering the development of chronic and/or degenerative conditions in a mammal, which comprises administering to a mammal in need of such treatment an effective amount of ascorbigen.
  • chronic and/or degenerative conditions include neurodegenerative diseases such as neurological decay, Alzheimer's disease or cognitive impairment; eye diseases, such as age-related macular degeneration, muscle decay, and muscle fatigue; and conditions associated with bone decay such as osteoporosis.
  • mammals are preferably humans, the invention is not limited to humans but includes other mammals, especially pets such as horses, dogs, cats and/or small animals, e.g. hamsters and/or guinea pigs.
  • ascorbigen may be administered to, e.g., a human adult (weighing about 70 kg) in an amount of up to about 10 to 1000 mg/day in one or several dosage units or servings.
  • the dosage for a human adult (weighing about 70 kg) is up to about 500 mg/day, especially up to about 100 to 200 mg/day.
  • the amount of ascorbigen contained therein is suitably no less than about 50 mg per serving. In another embodiment of the invention such amount is no less than about 100 mg per serving.
  • ascorbigen is administered as a pharmaceutical formulation such formulation may contain up to about 500 mg per solid dosage unit, e.g. per capsule.
  • serving denotes an amount of food and/or beverage normally ingested by a human adult with a meal at a time and may range, e.g., from about 100 g to about 500 g food and/or beverage.
  • composition according to the present invention can preferably be a nutraceutical composition.
  • nutraceutical as used herein denotes usefulness in both, the nutritional and pharmaceutical field of application.
  • “nutraceutical compositions” according to the present invention can serve as supplements to food, feed and beverages, dietary supplements and as pharmaceutical formulations which may be solid - such as capsules - or liquid - such as solutions or suspensions. It is evident from the foregoing that the term “nutraceutical composition” also comprises food, feed and beverages containing ascorbigen.
  • a multi-vitamin and mineral supplement may be added to the compositions according to the present invention, e.g. to maintain a good balanced nutrition or to obtain an adequate amount of an essential nutrient missing in some diets.
  • the multi-vitamin and mineral supplement may also be useful for disease prevention and protection against nutritional losses and deficiencies due to lifestyle patterns and common inadequate dietary patterns sometimes observed in diabetes.
  • the composition according to the present invention can be a food or beverage composition.
  • Beverages can be e.g. sports drinks, energy drinks or other soft drinks, or any other suitable beverage preparation, e.g. joghurt drinks, hot beverages or soups.
  • the beverage is an "instant beverage", i.e. a beverage which is produced - normally by the consumer themself - by stirring a powder into a liquid, usually milk or water.
  • Sports drink a beverage is meant which is consumed before, during and/or after physical exercise, mainly to hydrate as well as to (re-) store electrolytes, sugar and other nutrients. Sports drinks are usually isotonic, meaning they contain the same proportions of nutrients as found in the human body.
  • Energy drinks are beverages which contain (legal) stimulants, vitamins (especially B vitamins) and/or minerals with the intent to give the user a burst of energy.
  • Common ingredients include caffeine, guarana (caffeine from the Guarana plant) and/or taurine, various forms of ginseng, maltodextrin, inositol, carnitine, creatine, glucuronolactone, coenzyme Q10 and/or ginkgo biloba.
  • Some may contain high levels of sugar, or glucose, whereas others are sweetened completely or partially with a sugar alcohol and/or an artificial sweetener like Ca-cyclamate or Aspartame. Many such beverages are flavored and/or colored.
  • a soft drink is a drink that does not contain alcohol.
  • the term is used only for cold beverages. Hot chocolate, tea, and coffee are not considered soft drinks.
  • the term includes carbonated and non-carbonated drinks, e.g. mineral water or so-called “near water drinks", i.e. water-based beverages which have an additional benefit, e.g. a special flavor and/or further (functional) ingredients.
  • a "near water drink” is a mixture of water with very little juice.
  • Figure 1 shows the effect of ascorbigen stimulation on NADPH: Quinone oxidoreductase (NADPH:QO1 ) RNA expression in HepG2 cells.
  • the y-axis shows the fold induction. Data are average out of 3 independent experiments. * p ⁇ 0.05.
  • Figure 2 shows the effect of ascorbigen stimulation on NADPH: Quinone oxidoreductase (NADPH:QO1 ) enzymatic activity in HepG2 cells.
  • the y-axis shows the induction in %. Data are average out of 3 independent experiments. * p ⁇ 0.05.
  • Figure 3 shows the effect of ascorbigen against free radical challenge (Paraquat) on HepG2 cells survival.
  • the y-axis shows the survival rate in %. Data are average out of 3 independent experiments. p ⁇ 0.05 O Control (untreated) t Paraquat 500 ⁇ M
  • Figure 4 shows the effect of ascorbigen supplementation on RNA expression of NADPH: Quinone oxidoreductase 1 (N:QO1 ) and UDP-Glucuronosyltransferase in rat liver.
  • the y-axis shows the fold induction.
  • Figure 5 shows the effect of ascorbigen supplementation on NADPH: Quinone oxidoreductase 1 (N:QO1 ) and UDP-Glucuronosyltransferase enzymatic activity in rat liver.
  • the y-axis shows the induction rate in %. * p ⁇ 0.05
  • Liver cells HepG2 were treated with physiological amount of ascorbigen in a dose-dependent fashion for 16 hours. Cells were harvested and RNA isolated. The enzyme NAD(P)H:Quinone Oxidoreductasel (NQO1 ) was chosen as a representative for the family of phase Il enzymes. Quantification of NQO1 transcript was performed by real time PCR TaqMan®. Likewise, cells were harvested after stimulation with ascorbigen and the enzymatic activity of NQO1 was measured.
  • RNA and cellular microsomes were fractionated, isolated and stored at -80 0 C.
  • Transcriptional activation of the phase Il enzyme representatives NADPH:Quinone Oxidoreductase 1 and Glutathione-S-Transferase was assessed by quantitative PCR. Enzymatic activity was measured based on appropriate assays.
  • compositions may be prepared by conventional formulation procedures.
  • Soft gelatin capsules are prepared by conventional procedures containing as active ingredient 100 mg of ascorbigen per capsule.
  • Hard gelatin capsules are prepared by conventional procedures containing as active ingredient 100 mg of ascorbigen per capsule.
  • Food items may be prepared by conventional procedures containing ascorbigen in an amount of 50 mg to 500 mg per serving.
  • examples of such food items are soft drinks, bread, cookies, yoghurt, ice cream, and sweets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Use of ascorbigen to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.

Description

Novel use of Ascorbigen
The present invention relates to a novel use of ascorbigen; in particular it relates to the use of ascorbigen to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.
Ascorbigen is a known indol derivative which can be isolated from cabbage juice or synthetically prepared from ascorbic acid and 3-hydroxymethylindole. By systematic nomenclature, ascorbigen is a mixture of 2-C(1 H-indol-3-ylmethyl)-α-L-lyxo-3- hexulofuranosonic acid γ-lactone and 2-C(1 H-indol-3-ylmethyl)-α-L-xylo-3- hexulofuranosonic acid γ-lactone. As used herein, the term "ascorbigen" comprises the particular enantiomeres each individually as well as the above mentioned mixture and (stereo-) isomers and mixtures thereof.
Many genes which produce substance that are involved in the protection of cells against carcinogens, oxidants, and other toxic chemicals, are under the transcriptional control of a simple DNA regulatory element: the antioxidant response element (ARE). The signaling system leading to ARE activation has been partly elucidated, and nuclear factor erythroid 2-related factor 2 (Nrf2) has been identified as the key transcriptional factor that serves to transmit the inducer signal to ARE (J Biochem MoI Biol. 2004 Mar 31 ;37(2): 139-43.) It is now known that Nrf2, which is normally sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (Kepti ), dissociates from it upon exposure to ARE-mediated inducers, translocates to the nucleus, complexes with other nuclear factors, and binds to ARE. ARE-regulated gene products include Phase Il enzymes such as glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1 , UDP- glucuronosyltransferase, gamma-glutamate cysteine ligase, and hemeoxygenase-1. There is strong evidence that increased expression of ARE-regulated genes inhibits cancer development and degenerative processes (Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):267-81 ). Accordingly, ARE activators, such as oltipraz, anethole dithiolethione, sulforaphane, 6-methylsulphinylhexyl isothiocyanate, curcumin, caffeic acid phenethyl ester, 4'-bromoflavone, etc. are considered to have a potential in (chemo-) preventing and/or hindering the development of cancer, degenerative
CONFIRMATION COPY processes and/or age related diseases in a mammal, including neurological decay, Alzheimer, increasing oxidative stress, muscle decay.
Thus, in one aspect, the present invention relates to the use of ascorbigen to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.
In a further aspect, the invention relates to a method of inhibiting, preventing and/or hindering the development of chronic and/or degenerative conditions in a mammal, which comprises administering to a mammal in need of such treatment an effective amount of ascorbigen. Examples of such chronic and/or degenerative conditions include neurodegenerative diseases such as neurological decay, Alzheimer's disease or cognitive impairment; eye diseases, such as age-related macular degeneration, muscle decay, and muscle fatigue; and conditions associated with bone decay such as osteoporosis.
While for the purpose of the present invention mammals are preferably humans, the invention is not limited to humans but includes other mammals, especially pets such as horses, dogs, cats and/or small animals, e.g. hamsters and/or guinea pigs.
For the purposes of the invention, ascorbigen may be administered to, e.g., a human adult (weighing about 70 kg) in an amount of up to about 10 to 1000 mg/day in one or several dosage units or servings. In a particular embodiment of the invention, the dosage for a human adult (weighing about 70 kg) is up to about 500 mg/day, especially up to about 100 to 200 mg/day. If administered in a food or beverage the amount of ascorbigen contained therein is suitably no less than about 50 mg per serving. In another embodiment of the invention such amount is no less than about 100 mg per serving. If ascorbigen is administered as a pharmaceutical formulation such formulation may contain up to about 500 mg per solid dosage unit, e.g. per capsule.
The term "serving" as used herein denotes an amount of food and/or beverage normally ingested by a human adult with a meal at a time and may range, e.g., from about 100 g to about 500 g food and/or beverage.
The composition according to the present invention can preferably be a nutraceutical composition. The term "nutraceutical" as used herein denotes usefulness in both, the nutritional and pharmaceutical field of application. Thus, "nutraceutical compositions" according to the present invention can serve as supplements to food, feed and beverages, dietary supplements and as pharmaceutical formulations which may be solid - such as capsules - or liquid - such as solutions or suspensions. It is evident from the foregoing that the term "nutraceutical composition" also comprises food, feed and beverages containing ascorbigen.
A multi-vitamin and mineral supplement may be added to the compositions according to the present invention, e.g. to maintain a good balanced nutrition or to obtain an adequate amount of an essential nutrient missing in some diets. The multi-vitamin and mineral supplement may also be useful for disease prevention and protection against nutritional losses and deficiencies due to lifestyle patterns and common inadequate dietary patterns sometimes observed in diabetes.
The composition according to the present invention can be a food or beverage composition. Beverages can be e.g. sports drinks, energy drinks or other soft drinks, or any other suitable beverage preparation, e.g. joghurt drinks, hot beverages or soups. In a preferred embodiment of the present invention the beverage is an "instant beverage", i.e. a beverage which is produced - normally by the consumer themself - by stirring a powder into a liquid, usually milk or water.
By "sports drink" a beverage is meant which is consumed before, during and/or after physical exercise, mainly to hydrate as well as to (re-) store electrolytes, sugar and other nutrients. Sports drinks are usually isotonic, meaning they contain the same proportions of nutrients as found in the human body.
Energy drinks are beverages which contain (legal) stimulants, vitamins (especially B vitamins) and/or minerals with the intent to give the user a burst of energy. Common ingredients include caffeine, guarana (caffeine from the Guarana plant) and/or taurine, various forms of ginseng, maltodextrin, inositol, carnitine, creatine, glucuronolactone, coenzyme Q10 and/or ginkgo biloba. Some may contain high levels of sugar, or glucose, whereas others are sweetened completely or partially with a sugar alcohol and/or an artificial sweetener like Ca-cyclamate or Aspartame. Many such beverages are flavored and/or colored.
A soft drink is a drink that does not contain alcohol. In general, the term is used only for cold beverages. Hot chocolate, tea, and coffee are not considered soft drinks. The term includes carbonated and non-carbonated drinks, e.g. mineral water or so-called "near water drinks", i.e. water-based beverages which have an additional benefit, e.g. a special flavor and/or further (functional) ingredients. One simple example for a "near water drink" is a mixture of water with very little juice.
If the composition is prepared in form of one of the following food articles it is according to the present invention advantageous if the amount of ascorbigen in the composition is selected from the ranges given in the following table:
Figure imgf000005_0001
If the composition is prepared in form of a capsule it is according to the present invention advantageous if the amount of ascorbigen is selected from the ranges given in the following table:
Figure imgf000005_0002
The invention is further illustrated by Figures 1 to 5:
Figure 1 shows the effect of ascorbigen stimulation on NADPH: Quinone oxidoreductase (NADPH:QO1 ) RNA expression in HepG2 cells. The y-axis shows the fold induction. Data are average out of 3 independent experiments. * p< 0.05.
Figure 2 shows the effect of ascorbigen stimulation on NADPH: Quinone oxidoreductase (NADPH:QO1 ) enzymatic activity in HepG2 cells. The y-axis shows the induction in %. Data are average out of 3 independent experiments. * p< 0.05.
Figure 3 shows the effect of ascorbigen against free radical challenge (Paraquat) on HepG2 cells survival. The y-axis shows the survival rate in %. Data are average out of 3 independent experiments. p< 0.05 O Control (untreated) t Paraquat 500μM
X Paraquat 500μM + ascorbigen 100μM
Figure 4 shows the effect of ascorbigen supplementation on RNA expression of NADPH: Quinone oxidoreductase 1 (N:QO1 ) and UDP-Glucuronosyltransferase in rat liver. The y-axis shows the fold induction. p< 0.05
O Control (untreated)
▲ N:QO1 (ascorbigen) | UDP-Glucuronosyltransferase (ascorbigen)
Figure 5 shows the effect of ascorbigen supplementation on NADPH: Quinone oxidoreductase 1 (N:QO1 ) and UDP-Glucuronosyltransferase enzymatic activity in rat liver. The y-axis shows the induction rate in %. * p< 0.05
O Control (untreated)
A N:QO1 (ascorbigen)
| UDP-Glucuronosyltransferase (ascorbigen)
The invention is further illustrated by the following examples. Examples:
The efficacy of ascorbigen in the selective activation of phase Il enzymes in vitro and in vivo was demonstrated as shown by tests set forth below.
In vitro test model
Liver cells HepG2 were treated with physiological amount of ascorbigen in a dose- dependent fashion for 16 hours. Cells were harvested and RNA isolated. The enzyme NAD(P)H:Quinone Oxidoreductasel (NQO1 ) was chosen as a representative for the family of phase Il enzymes. Quantification of NQO1 transcript was performed by real time PCR TaqMan®. Likewise, cells were harvested after stimulation with ascorbigen and the enzymatic activity of NQO1 was measured.
Results
Compared to control cells (no treatment), cells stimulated with increasing amount of ascorbigen show a dose-dependent increase of NQO1 transcriptional activity (Figure 1). These results are also confirmed at the enzymatic level with a significant increase of NQO1 activity (Figure 2).
In vivo test model Male Wistar rats weighing 200 - 220 g, after 4 days of labor acclimation were randomized into groups of 10 animals. Following treatment groups have been analyzed i) Control animals receiving placebo, ii) Test animals receiving 5mg/rat/day of Ascorbigen. The compound was administrated daily by gavages for 7 consecutive days. Food and water were given ad libitum during the experiment. The activation of phase Il enzymes was measured as following:
Livers were collected; RNA and cellular microsomes were fractionated, isolated and stored at -800C. Transcriptional activation of the phase Il enzyme representatives NADPH:Quinone Oxidoreductase 1 and Glutathione-S-Transferase was assessed by quantitative PCR. Enzymatic activity was measured based on appropriate assays.
Results
Compared to control animals (placebo), rats daily supplemented with Ascorbigen, showed a significant increase in liver's mRNA expression of NADPH:Quinone Oxidoreductase 1 and Glutathione-S-Transferase (figure 4). These results were subsequently confirmed by appropriate enzymatic assays. Both phase Il enzymes showed a significant increase in their enzymatic activities (figure 5). Pharmaceutical compositions may be prepared by conventional formulation procedures.
Example 1 Soft gelatin capsule
Soft gelatin capsules are prepared by conventional procedures containing as active ingredient 100 mg of ascorbigen per capsule.
Example 2
Hard gelatin capsule
Hard gelatin capsules are prepared by conventional procedures containing as active ingredient 100 mg of ascorbigen per capsule.
Example 3
Food items may be prepared by conventional procedures containing ascorbigen in an amount of 50 mg to 500 mg per serving. Examples of such food items are soft drinks, bread, cookies, yoghurt, ice cream, and sweets.

Claims

Claims:
1. Use of ascorbigen to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.
2. Use according to claim 1 wherein the condition is a neurodegenerative disease.
3. Use according to claim 1 wherein the condition is selected from neurological decay, Alzheimer's disease and/or cognitive impairment.
4. Use according to claim 1 wherein the condition is an eye disease, especially age- related macular degeneration.
5. Use according to claim 1 wherein the condition is muscle decay or muscle fatigue.
6. Use according to claim 1 wherein the condition is associated with bone decay.
7. Use according to claim 6 wherein the condition is osteoporosis.
8. Use of ascorbigen for the manufacture of a composition to inhibit, prevent and/or hinder the development of chronic and/or degenerative conditions in a mammal.
9. Use according to claim 8 wherein the composition is a nutraceutical composition.
10. Use according to claim 8 wherein the composition is a food or beverage or supplement to food or beverage.
11. Use according to any of the claims 9 or 10 wherein the amount of ascorbigen present in the composition is appropriate to provide a dosage of 10 to 1000 mg per day for an adult in one or several dosage units or servings.
12. A method for inhibiting, preventing and/or hindering the development of chronic and/or degenerative conditions in a mammal which comprises administering to a mammal in need of such treatment an effective amount of ascorbigen.
13. The method according to claim 12 wherein the amount of ascorbigen is appropriate to provide a dosage of 10 to 1000 mg per day for an adult.
PCT/EP2007/002858 2006-03-31 2007-03-30 Novel use of ascorbigen WO2007112964A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06006814 2006-03-31
EP06006814.5 2006-03-31

Publications (1)

Publication Number Publication Date
WO2007112964A1 true WO2007112964A1 (en) 2007-10-11

Family

ID=38091712

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2007/002857 WO2007112963A1 (en) 2006-03-31 2007-03-30 Novel use of ascorbigen
PCT/EP2007/002858 WO2007112964A1 (en) 2006-03-31 2007-03-30 Novel use of ascorbigen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002857 WO2007112963A1 (en) 2006-03-31 2007-03-30 Novel use of ascorbigen

Country Status (1)

Country Link
WO (2) WO2007112963A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107929696A (en) * 2017-12-14 2018-04-20 薛建民 A kind of external medicine composition for loose flesh bonesetting of subsiding a swelling and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017768A1 (en) * 1997-10-08 1999-04-15 Designed Nutritional Products, Inc. Treatment of fibromyalgia and related disorders
DE10308298A1 (en) * 2003-02-26 2004-09-09 Kullmer, Thomas, Priv. Doz. Dr. med. Production of a plant preparation useful for treating cancer comprises extracting glucosinolates from plant material and enzymatically hydrolyzing the glucosinolates to isothiocyanates
RU2235543C1 (en) * 2003-01-28 2004-09-10 Государственное учреждение Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе Method for increasing inspecific body resistance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017768A1 (en) * 1997-10-08 1999-04-15 Designed Nutritional Products, Inc. Treatment of fibromyalgia and related disorders
RU2235543C1 (en) * 2003-01-28 2004-09-10 Государственное учреждение Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе Method for increasing inspecific body resistance
DE10308298A1 (en) * 2003-02-26 2004-09-09 Kullmer, Thomas, Priv. Doz. Dr. med. Production of a plant preparation useful for treating cancer comprises extracting glucosinolates from plant material and enzymatically hydrolyzing the glucosinolates to isothiocyanates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Verwendung von Ascorbigen als Anti-Aging Mittel", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 24 February 2005 (2005-02-24), XP013023450, ISSN: 1533-0001 *
PREOBRAZHENSKAYA M N ET AL: "Ascorbigen and other indole-derived compounds from Brassica vegetables and their analogs as anticarcinogenic and immunomodulating agents", PHARMACOLOGY AND THERAPEUTICS, vol. 60, no. 2, 1993, pages 301 - 313, XP002436766, ISSN: 0163-7258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107929696A (en) * 2017-12-14 2018-04-20 薛建民 A kind of external medicine composition for loose flesh bonesetting of subsiding a swelling and its preparation method and application

Also Published As

Publication number Publication date
WO2007112963A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
JP3953513B2 (en) Piperine-containing composition
JP5614817B2 (en) Combination of hydroxytyrosol to enhance mitochondrial function and energy production
CN101484158B (en) Senescence inhibitor
ES2625255T3 (en) Preparation, which comprises a composition containing polyphenol, and isomaltulose
US7976879B2 (en) Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
EP3159353A1 (en) Cyclic dipeptide-containing composition
TWI383753B (en) Composition for enhancing exercise ability
US20040171624A1 (en) Pharmaceutical composition for treating mood disorders
JP2022113789A (en) Composition for promoting tissue differentiation, and composition for improving liver function
KR20240057401A (en) Paraxanthin-based caffeine substitute composition and method of use thereof in slow caffeine metabolizers
CN115279209A (en) Coenzyme Q production promoter and coenzyme Q production promoting method
JP2002265359A (en) Kainic acid type glutamate receptor-shielding agent, ampa type glutamate receptor shielding agent, brain- protecting agent and food or drink having brain- protecting function
JP5922862B2 (en) Mitochondrial function improver
US11446317B2 (en) Inositol phosphate-containing composition
US20210353659A1 (en) Composition for preventing or treating muscular diseases, or for improving muscular functions, containing gagnlioside
WO2007112964A1 (en) Novel use of ascorbigen
EP3366292B1 (en) Composition for preventing or treating obesity containing alpha-lipoic acid and n-acetylcysteine as active ingredients
JP2008247858A (en) Dietary composition for oral administration
JP6391959B2 (en) Non-alcoholic steatohepatitis ameliorating agent and ameliorating nutrition composition
ES2765238T3 (en) IGF-1 production promoting agent
CA2459240C (en) Pharmaceutical composition for treating mood disorders
JP5048258B2 (en) Rebound inhibitor
KR102666724B1 (en) Composition containing inositol phosphate
WO2020046363A1 (en) Dietary supplement formula and methods of using the same
KR20240056735A (en) soluble phytin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723800

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07723800

Country of ref document: EP

Kind code of ref document: A1